Transgenomic Posts 22 Percent Decline in PGx Business, but Predicts Segment 'Swell' in Coming Months
May 18, 2011
Transgenomic Posts 22 Percent Decline in PGx Business, but Predicts Segment 'Swell' in Coming Months
A Transgenomic official said the company has signed deals "for a number of significant high-value projects" with pharmaceutical firms, which promise to "swell the [segment to] $1.5 million or more in the second quarter, plus [bring in] significant revenues throughout the remainder of the year."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Transgenomic Launches NGS-Based Mitochondrial Disease Test, Developing Autism Risk Test
June 21, 2011 / Clinical Sequencing News - Transgenomic Improves Mutation Detection Limit for Sanger Sequencing
April 26, 2011 / Clinical Sequencing News - Transgenomic Scoops Up Clinical Data's Genetic Tests, PGx Products at 'Fair Price' of $15.4M
December 1, 2010 / Pharmacogenomics Reporter - Transgenomic Using STTR Grant to Explore Ice-Cold-PCR Detection of Pancreatic Cancer Mutations
August 16, 2012 / PCR Insider - Transgenomic Teams With MCW to Offer NGS Testing Services
July 30, 2012 / GenomeWeb Daily News